13.61
Schlusskurs vom Vortag:
$13.97
Offen:
$12.89
24-Stunden-Volumen:
4.79M
Relative Volume:
4.32
Marktkapitalisierung:
$599.18M
Einnahmen:
$78.02M
Nettoeinkommen (Verlust:
$-73.37M
KGV:
-10.31
EPS:
-1.32
Netto-Cashflow:
$-62.06M
1W Leistung:
-3.61%
1M Leistung:
-26.43%
6M Leistung:
-21.15%
1J Leistung:
-38.02%
Beta Bionics Inc Stock (BBNX) Company Profile
Firmenname
Beta Bionics Inc
Sektor
Branche
Telefon
949-427-7785
Adresse
11 HUGHES, IRVINE
Compare BBNX vs ABT, SYK, MDT, BSX, EW
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
|
BBNX
Beta Bionics Inc
|
13.61 | 615.02M | 78.02M | -73.37M | -62.06M | -1.32 |
|
ABT
Abbott Laboratories
|
113.29 | 195.21B | 44.33B | 6.48B | 6.92B | 3.7033 |
|
SYK
Stryker Corp
|
377.32 | 141.28B | 25.12B | 3.25B | 4.28B | 8.3984 |
|
MDT
Medtronic Plc
|
98.49 | 123.60B | 35.48B | 4.64B | 5.41B | 3.5856 |
|
BSX
Boston Scientific Corp
|
76.28 | 113.14B | 20.08B | 2.89B | 3.82B | 1.9391 |
|
EW
Edwards Lifesciences Corp
|
78.98 | 45.52B | 6.07B | 1.06B | 799.60M | 1.8527 |
Beta Bionics Inc Stock (BBNX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-02-09 | Eingeleitet | UBS | Buy |
| 2026-01-27 | Eingeleitet | TD Cowen | Hold |
| 2026-01-09 | Herabstufung | BofA Securities | Buy → Neutral |
| 2025-10-21 | Fortgesetzt | Stifel | Buy |
| 2025-10-01 | Hochstufung | Goldman | Neutral → Buy |
| 2025-06-16 | Eingeleitet | Truist | Buy |
| 2025-06-12 | Eingeleitet | Lake Street | Buy |
| 2025-05-30 | Eingeleitet | Goldman | Neutral |
| 2025-05-30 | Eingeleitet | Wolfe Research | Outperform |
| 2025-02-24 | Eingeleitet | BofA Securities | Buy |
| 2025-02-24 | Eingeleitet | Lake Street | Buy |
| 2025-02-24 | Eingeleitet | Leerink Partners | Outperform |
| 2025-02-24 | Eingeleitet | Piper Sandler | Overweight |
| 2025-02-24 | Eingeleitet | Stifel | Buy |
| 2025-02-20 | Eingeleitet | Ladenburg Thalmann | Neutral |
| 2025-02-20 | Eingeleitet | Robert W. Baird | Neutral |
Alle ansehen
Beta Bionics Inc Aktie (BBNX) Neueste Nachrichten
Stifel cuts Beta Bionics stock price target on guidance review - Investing.com Nigeria
Stifel cuts Beta Bionics stock price target on guidance review By Investing.com - Investing.com South Africa
Midday Stock Roundup: Staar Surgical up on FDA approval - Orange County Business Journal
TD Cowen cuts Beta Bionics stock price target on revenue timing - Investing.com
BBNX Analyst Rating Update: Baird Lowers Price Target to $14.00 - GuruFocus
TD Cowen cuts Beta Bionics stock price target on revenue timing By Investing.com - Investing.com India
Expert Outlook: Beta Bionics Through The Eyes Of 7 Analysts - Benzinga
Beta Bionics, Inc. Q4 2025 Earnings Call Summary - Yahoo Finance
Hold Rating Maintained as In-Line Results and Improving Margins Offset Near-Term Prescription Headwinds - TipRanks
Beta Bionics Q4 Revenue Jumps 57%; Guides FY26 Revenue Growth Of 30% To 35% - Nasdaq
Beta Bionics Announces Fourth Quarter and Full Year 2025 Financial Results and Introduces Annual Guidance for Full Year 2026 - The Globe and Mail
Beta Bionics (BBNX) Q4 2025 Earnings Transcript - The Globe and Mail
Beta Bionics Shares Edge Higher After Q4 Revenue Jumps 57%, Full-Year Sales Top $100 Million - AlphaStreet News
INVESTIGATION REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Beta Bionics - Seeking Alpha
Beta Bionics Q4 Earnings Call Highlights - Yahoo Finance
Beta Bionics, Inc. (BBNX) Reports Q4 Loss, Tops Revenue Estimates - Bitget
Beta Bionics Q4 Loss Narrows, Revenue Rises; Sets Guidance - marketscreener.com
Beta Bionics Q4 2025 Earnings Call Transcript - MarketBeat
Pomerantz Law Firm Investigates Claims On Behalf of Investors of Beta Bionics, Inc.BBNX - marketscreener.com
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Beta Bionics, Inc. - GlobeNewswire Inc.
Earnings Preview For Beta Bionics - Benzinga
Earnings To Watch: Beta Bionics Inc (BBNX) Reports Q4 2025 Resul - GuruFocus
BBNX SECURITIES ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Beta Bionics - Nasdaq
How cyclical is Beta Bionics Inc.’s revenue streamDividend Hike & Verified Chart Pattern Trade Signals - mfd.ru
Why Beta Bionics Inc. stock appeals to dividend seekersJuly 2025 Analyst Calls & Stock Portfolio Risk Management - mfd.ru
Will Beta Bionics Inc. stock remain a Wall Street favoriteNew Guidance & Risk Controlled Swing Alerts - mfd.ru
INVESTOR NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Beh - GuruFocus
INVESTOR NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Beta Bionics - Barchart.com
Why is Beta Bionics Inc. stock going downWeekly Gains Report & Safe Entry Zone Identification - mfd.ru
Does Beta Bionics Inc. have consistent dividend growthPortfolio Update Report & Weekly Breakout Watchlists - mfd.ru
UBS Group Upgrades Beta Bionics (NASDAQ:BBNX) to "Strong-Buy" - MarketBeat
Will Beta Bionics, Inc. (BBNX) Report Negative Earnings Next Week? What You Should Know - Finviz
Beta Bionics (NASDAQ:BBNX) Trading Up 7.9%Here's What Happened - MarketBeat
Essex Investment Management Co. LLC Takes Position in Beta Bionics, Inc. $BBNX - MarketBeat
Beta Bionics (NASDAQ:BBNX) Shares Gap UpTime to Buy? - MarketBeat
Resistance Check: How liquid is Beta Bionics Inc stockSwing Trade & Real-Time Chart Pattern Alerts - baoquankhu1.vn
UBS Initiates Coverage on Beta Bionics With Buy Rating, $24 Price Target - marketscreener.com
Beta Bionics, Inc. (NASDAQ:BBNX) Given Average Recommendation of "Moderate Buy" by Brokerages - MarketBeat
UBS initiates coverage on Beta Bionics stock with Buy rating By Investing.com - Investing.com Canada
UBS initiates coverage on Beta Bionics stock with Buy rating - Investing.com Nigeria
Faruqi & Faruqi Investigates Aquestive Therapeutics for Investor Losses - intellectia.ai
Beta Bionics, Inc.'s (NASDAQ:BBNX) Popularity With Investors Under Threat As Stock Sinks 58% - simplywall.st
Artificial Pancreas System Market is expected to reach US$ - openPR.com
Stifel Nicolaus Lowers Beta Bionics (NASDAQ:BBNX) Price Target to $25.00 - MarketBeat
SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Beta Bionics - ChartMill
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Beta Bionics, Inc.BBNX - Chartmill
Beta Bionics receives FDA warning letter - MedTech Dive
TD Cowen reiterates Hold rating on Beta Bionics stock amid FDA warning letter - Investing.com Australia
TD Cowen reiterates Hold rating on Beta Bionics stock amid FDA warning letter By Investing.com - Investing.com South Africa
Beta Bionics stock holds steady as TD Cowen reiterates $17 price target By Investing.com - Investing.com South Africa
Beta Bionics stock holds steady as TD Cowen reiterates $17 price target - Investing.com Canada
Finanzdaten der Beta Bionics Inc-Aktie (BBNX)
Umsatz
Nettogewinn
Free Cashflow
ENV
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):